ViaCyte's potential diabetes 'cure' gets another $6m to move into human trials
This article was originally published in Clinica
ViaCyte's stem cell-based diabetes product, which the San Diego-based company has said could reduce or eliminate the need for pharmaceutical insulin, has moved into clinical trials earlier than expected, helped by $6 million in new funds. This brings the total invested by the Juvenile Diabetes Research Foundation (JDRF) to $7 million, while the California Institute for Regenerative Medicine (CIRM) has financed nearly $40 million in preclinical work for the VC-01 therapeutic and device combination product.
You may also be interested in...
The fast-dissolving tablet will launch in early March. Its list price is not available but based on pricing for Allergan’s oral anti-CGRP Ubrelvy, ICER has said Biohaven’s rimegepant is likely to be cost-effective.
After eptinezumab’s approval in the US, EVP Peter Anastasiou told Scrip it will take time to change migraine doctors’ prescribing habits, but he expects CGRP inhibitors to become mainstay preventative treatments. Vyepti’s list price is about $1,000 below its competitors’ launch prices.
ICER’s final report on new acute migraine treatments said the drugs are similarly beneficial when patients don’t respond to or can’t take triptans, but found Reyvow is not as cost effective as Ubrelvy and rimegepant.